Immunicum has successfully completed in vitro studies and studies in rat models. Both substantial prophylactic and therapeutic effects were shown without any adverse side effects (Cancer Immunology and Immunotherapy 2008,57,suppl1, p10).

Immunicum recently received an MPA-approval to initiate a clinical phase I/II-study (evaluating both tolerance and effect) on its COMBIG-concept on 12 metastatic renal cell cancer patients by Q1 2012.